New 3D method may improve tumor measurement accuracy
NCT ID NCT07319767
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 120 adults with breast, pancreatic, or biliary cancer to see if a new 3D measurement method (TDTP-RECIST) is better than the standard way (RECIST 1.1) for tracking tumor shrinkage before surgery. Researchers compared imaging results with actual tumor tissue removed during surgery. The goal is to help doctors choose more accurate tools for assessing treatment response in irregularly shaped tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
120 people
The number who actually took part.
- Started
-
May 2024
- Finished
-
Oct 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
This study includes adults who were treated and had surgery at Zhongshan Hospital, Fudan University (Shanghai, China) Shenzhen University General Hospital (Shenzhen, China), Tianjin Cancer Hospital Airport Hospital (Tianjin, China), between May 2019 to Dec. 2024. All participants had one of the following cancers: biliary tract cancer (intrahepatic or hilar cholangiocarcinoma, or gallbladder cancer), breast cancer (invasive ductal carcinoma), or pancreatic ductal adenocarcinoma. They received treatment given before surgery to shrink the tumor (neoadjuvant or "conversion" therapy) and then underwent surgical removal of the tumor.
- Ages
-
18 to 80 years
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Pathologically confirmed malignancy of one of the following types: biliary tract cancer (intrahepatic cholangiocarcinoma, hilar cholangiocarcinoma, or gallbladder cancer), breast cancer, or pancreatic ductal adenocarcinoma 2. Age 18 to 80 years (inclusive), any sex 3. Received neoadjuvant or conversion therapy before surgery; no prior anti-cancer therapy before that course 4. Underwent tumor surgical resection or biopsy after completion of neoadjuvant/conversion therapy 5. Available baseline and preoperative imaging with the same modality (contrast-enhanced CT or MRI) at both time points for response evaluation 6. Complete postoperative pathology report and follow-up data available Exclusion Criteria: 1. History of another malignancy or concurrent multiple primary cancers 2. Missing imaging or inconsistent imaging evaluation across time points (e.g., absent scans or differing modalities that preclude paired assessment)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Biliary cancer (cholangiocarcinoma, gall bladder cancer) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongshan Hospital, Fudan University
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?
- Tiny magnetic seeds could guide surgeons to the right lymph node
- New PET tracer aims to light up hidden cancer targets
- Gut bacteria supplement tested against chemo hair loss
- Can a mindfulness program boost Self-Compassion in breast cancer survivors?
- Can a Decades-Old Anti-Inflammatory drug quiet the joint pain that drives women off breast cancer therapy?